Keyword: drug plan management

503 results found
Editorial: Of drugs and dentists: The best-laid plans or a political ploy?

It’s not often that the issues relevant to benefits plans emerge as an area of focus in the political realm. But with votes up for grabs and politicians eager to find any way to harness them, it appears issues of drugs and dental care are moving up the political agenda. In the federal arena, the […]

Specialty drugs made up 31% of total private plan drug spending in 2017

Employer-sponsored drug plan spending increased 2.5 per cent from 2016 to 2017, according to Express Scripts Canada’s latest drug trend report. “The trend was fairly moderate in terms of the year-over-year increase that we saw,” says John Herbert, director of strategy, product development and clinical services at Express Scripts. “But there’s still cause for concern when we […]

Federal patent changes to add new costs to drug plans, report predicts

New federal legislation around pharmaceutical patents will impose significant costs on public and private drug plans, the parliamentary budget officer is predicting. The legislation would have cost drug plans and consumers an extra $392 million in 2015 had it been in place that year, the report, released in late April, estimates. Of that, $214 million […]

Pharmacy benefits managers to play growing role in boosting outcomes, addressing costs

Health-care costs are projected to increase a whopping 130 per cent over the next eight years after a period of relatively flat growth, according to a study published by Mercer in 2017. One of the key drivers is rising drug costs, with expensive specialty medications and gene therapies making up the majority of new products in development. So […]

  • April 30, 2018 September 13, 2019
  • 14:22
RBC Insurance to study pharmacogenetic testing for biologic drugs

When RBC Insurance Services Inc. began offering pharmacogenetic testing to its group benefits plan sponsors and began a clinical study of the issue in relation to biologic drugs recently, it did so with a few things in mind. “There’s a number of issues we’re looking at as we consider how to approach addressing those issues, […]

Great-West Life expands mental-health coverage, adds paramedical benefits for staff

Great-West Life Assurance Co. is expanding its benefits offering to employees, including increasing the maximum coverage for mental-health services to $5,000 a year, eliminating prescription drug deductibles on select plans and adding new paramedical services. “Our company believes in the importance of making a difference in the lives of our employees during moments that matter, which is why […]

  • By: Staff
  • April 19, 2018 September 13, 2019
  • 16:30
Virtual care among ‘dramatic change’ predicted for benefits plans in future

One of the biggest changes in the benefits industry over the next five years will be the movement towards virtual care as a standalone category, said Tim Clarke at Benefits Canada‘s Benefits & Pension Summit in Toronto on Monday. “Whether you’re talking about telemedicine, whether you’re talking about virtual [cognitive behavioural therapy], you think about […]

A look at one company’s experience with pharmacogenetic testing

At General Electric Co. Canada, part of Dr. Sol Sax’s job as consultant and medical director is to support and refine the company’s disability management process. That process includes everything from how the company helps to prevent workers from going on disability to monitoring them while they’re away and supporting their return to work. As part of its […]

Lower generic prices not a cure for drug cost pressures

The announcement in late January that 70 of the most commonly prescribed drugs will see their prices fall by as much as 40 per cent on April 1 was certainly welcome news for plan sponsors. The deal, reached by the pan-Canadian Pharmaceutical Alliance and the Canadian Generic Pharmaceutical Association, will bring the cost of some generic products down […]

  • March 26, 2018 September 13, 2019
  • 16:14
How changing public coverage could affect the pharmaceuticals industry

The hepatitis C hump is over. Since 2014, Health Canada has approved several promising medications for the disease. While the direct-acting antivirals offer cure rates of more than 90 per cent, they cost tens of thousands of dollars, and benefits plans felt the pinch. But now, “after an initial spike in treatment requests, claims have […]